No Data
No Data
BioCryst Says Orladeyo Granted Approval in Mexico
BioCryst Pharmaceuticals (BCRX) said Monday that it has received approval for Orladeyo from Mexico's Federal Commission for Protection against Health Risks for the prophylaxis of hereditary angioedema
Express News | Orladeyo® (Berotralstat) Approved in Mexico
ORLADEYO (Berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has
Here's What Analysts Are Forecasting For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) just released its quarterly report and things are looking bullish. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutor
Express News | BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat)
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients With HAE Following Initiation of ORLADEYO (Berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat)
Jaguar8 : This I like! Good for patients and healthcare institutions
TrytosaveabitOP Jaguar8: Yup yup!